Organon & Co.
For the period ended Sep 30, 2026. Filed Oct 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Inventories
- Inventories
Inventories consisted of:
| ($ in millions) | September 30, 2026 | December 31, 2025 |
|---|---|---|
| Finished goods | $702 | $751 |
| Raw materials | 12 | 14 |
| Work in process | 843 | 791 |
| Supplies | 79 | 81 |
| Total (approximates current cost) | $1,636 | $1,637 |
| Increase to last in, first out (“LIFO”) costs | 2 | 5 |
| Total inventories | $1,638 | $1,642 |
| Recognized as: | ||
| Inventories | $1,355 | $1,406 |
| Other assets | 283 | 236 |
| Inventories valued under the LIFO method | 131 | 114 |
In connection with the divestiture of Jada in January 2026, $8 million of inventory was reclassified to Assets held for sale on the Consolidated Balance Sheet as of December 31, 2025.
As part of the Dermavant Sciences Ltd. (“Dermavant”) acquisition in 2024, the Company acquired $97 million of inventory, which included a $63 million purchase accounting inventory fair value adjustment. As of September 30, 2026, the amount has been fully expensed. As of December 31, 2025, there was $7 million remaining in inventory related to the fair value adjustment.
Amounts recognized as Other assets are comprised primarily of raw materials and work in process inventories and are not expected to be converted to finished goods that will be sold within one year. The Company has long-term vendor supply contracts that include certain annual minimum purchase commitments.
-15-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.